The other good one was this from Fox's Tubi?
But anyone who has a dog roll over on the Apple TV remote knows this feeling:
But anyone who has a dog roll over on the Apple TV remote knows this feeling:
GBA Presents: RADIO SAVANT-!
- Thread starter stonedinvestor
- Start date
SOUN Mar 2023 4.000 call
OPR - OPR Delayed Price.
0.7500-0.1000 (-11.76%)<------- GO TIME VAN!
As of 10:19AM EST. Market open.
Certainly I do not have the last part of the system in place-- the good news coming...
+ I'm experimenting with something here- which is using a lack of big thrust down as a tell///
meaning with the stk down 9% and being sold off by mo mo AI investors... you would of thought the $4's would be down 20% but hey were only down 11%<----
OPR - OPR Delayed Price.
0.7500-0.1000 (-11.76%)<------- GO TIME VAN!
As of 10:19AM EST. Market open.
Certainly I do not have the last part of the system in place-- the good news coming...
+ I'm experimenting with something here- which is using a lack of big thrust down as a tell///
meaning with the stk down 9% and being sold off by mo mo AI investors... you would of thought the $4's would be down 20% but hey were only down 11%<----
WATCH THESE TODAY-!
TIME FOR A CRUISE?
Royal Caribbean is tipped by Macquarie to keep rallying
Feb. 13, 2023 10:21 AM ET Royal Caribbean Cruises Ltd. (RCL)
Macquarie Research reiterated an Outperform rating on Royal Caribbean Cruises (NYSE:RCL) on Monday following the company's Q4 update that included management pointing out that the seven biggest booking weeks in the company's history have occurred since November.
Royal Caribbean is tipped by Macquarie to keep rallying
Feb. 13, 2023 10:21 AM ET Royal Caribbean Cruises Ltd. (RCL)
Macquarie Research reiterated an Outperform rating on Royal Caribbean Cruises (NYSE:RCL) on Monday following the company's Q4 update that included management pointing out that the seven biggest booking weeks in the company's history have occurred since November.
CHILDREN PAPA IS DRUNK. HE JUST SHOOED AwAY TWO DEER WHO KNEW HIM SO WELL THEY STOPPED TURNED AND Advanced on him.Nostrils flaring... Whity's babies?
I think it's this other crazy one.. no fear at all of humans...
anyway. When I was gone Lizard King went long!!!!
That MFer!!!!!!!
GBA Long alert****S&P 500 (^GSPC)<--- Fiddle master play!!! - UP
SNP - SNP Real Time Price.
4,098.39-19.47 (-0.47%)<-- "What? now up stoney are you ok?"<-- actual quote****
As of 02:51PM EST. Market open.
SP500 S&P 500 Index- SLOW & STEADY WINS THE RACE
- THE LIZARD KING
$4,114.83 +24.37 (+0.60%)10:27 AM 02/13/23
S&P Complete Indices | $USD | Realtime
PRVB SELL THE NEWS MOMENT?
Provention Bio Announces Completion of $35 Million Equity Investment from Sanofi US
Mon, February 13, 2023, 7:30 AM EST
In this article:
PRVB
-5.58%
Companies collaborating to expand access to TZIELD™ (teplizumab-mzwv), the first approved disease-modifying therapy for type 1 diabetes
RED BANK, N.J., Feb. 13, 2023 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced the closing of the $35 million equity investment from Sanofi US under the previously announced Co-Promotion Agreement and Securities Purchase Agreement (the "Purchase Agreement").
(PRNewsfoto/Provention Bio, Inc.)
"Our Sanofi co-promotion agreement, together with this equity investment, bring significant financial and human capital to Provention in support of our commercial launch of TZIELD (teplizumab-mzwv), more than doubling our original field presence in the U.S.," said Jason Hoitt, Chief Commercial Officer, Provention Bio. "TZIELD is the first immunomodulatory therapy approved to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and pediatric patients aged 8 years and older with stage 2 T1D. TZIELD's recent FDA approval advances our purpose to intercept autoimmunity in its earlier stages, rather than waiting to manage end-stage disease when symptoms, irreversible tissue damage, and serious complications appear. Over the past few months, we have been partnering with our colleagues at Sanofi to increase awareness and access to TZIELD. The Provention Bio COMPASS™ patient support team has been working closely with prescribing physicians and their eligible T1D patients to efficiently navigate reimbursement and insurance coverage processes and gain access to our game-changing Stage 2 T1D therapeutic option."
Olivier Bogillot, Head of U.S. General Medicines, Sanofi, stated, "We are excited to continue supporting Provention Bio in the U.S. commercial launch of TZIELD, the first approved disease-modifying therapy for type 1 diabetes.
Provention Bio Announces Completion of $35 Million Equity Investment from Sanofi US
Mon, February 13, 2023, 7:30 AM EST
In this article:
PRVB
-5.58%
Companies collaborating to expand access to TZIELD™ (teplizumab-mzwv), the first approved disease-modifying therapy for type 1 diabetes
RED BANK, N.J., Feb. 13, 2023 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced the closing of the $35 million equity investment from Sanofi US under the previously announced Co-Promotion Agreement and Securities Purchase Agreement (the "Purchase Agreement").
(PRNewsfoto/Provention Bio, Inc.)
"Our Sanofi co-promotion agreement, together with this equity investment, bring significant financial and human capital to Provention in support of our commercial launch of TZIELD (teplizumab-mzwv), more than doubling our original field presence in the U.S.," said Jason Hoitt, Chief Commercial Officer, Provention Bio. "TZIELD is the first immunomodulatory therapy approved to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and pediatric patients aged 8 years and older with stage 2 T1D. TZIELD's recent FDA approval advances our purpose to intercept autoimmunity in its earlier stages, rather than waiting to manage end-stage disease when symptoms, irreversible tissue damage, and serious complications appear. Over the past few months, we have been partnering with our colleagues at Sanofi to increase awareness and access to TZIELD. The Provention Bio COMPASS™ patient support team has been working closely with prescribing physicians and their eligible T1D patients to efficiently navigate reimbursement and insurance coverage processes and gain access to our game-changing Stage 2 T1D therapeutic option."
Olivier Bogillot, Head of U.S. General Medicines, Sanofi, stated, "We are excited to continue supporting Provention Bio in the U.S. commercial launch of TZIELD, the first approved disease-modifying therapy for type 1 diabetes.
MAN WE HAD THE TRADE JUST NOT THE TIMING!!
ABNB Mar 2023 130.000 call
OPR - OPR
1.8700+0.6000 (+47.24%)<----------
As of 10:35AM EST.
AGAIN SMALL AMOUNT: BUT LETS ADD PRVB
THIS HAD A $10.50 PRINT THIS AM!!!!!
Provention Bio, Inc. (PRVB)
NasdaqGS - NasdaqGS Real Time Price.
9.82-0.58 (-5.58%)<------ GO TIME!
As of 10:37AM EST.
THIS HAD A $10.50 PRINT THIS AM!!!!!
Provention Bio, Inc. (PRVB)
NasdaqGS - NasdaqGS Real Time Price.
9.82-0.58 (-5.58%)<------ GO TIME!
As of 10:37AM EST.
Toast, Inc. (TOST) LIFT OFF
NYSE - Nasdaq Real Time Price.
24.00+1.20 (+5.26%)
As of 10:44AM EST.
NYSE - Nasdaq Real Time Price.
24.00+1.20 (+5.26%)
As of 10:44AM EST.
Fastly rises 19.1% 10:00 FSLY
I SCREWED UP AND TOOK MY EYE OF THE BALL THIS WAS EASY MONEY FROM THIS AM MARKET CALL...
I SCREWED UP AND TOOK MY EYE OF THE BALL THIS WAS EASY MONEY FROM THIS AM MARKET CALL...